Abstract
A multimodal, β-amyloid-targeted contrast agent was synthesized and studied in vitro. The agent has a higher relaxivity than a clinically approved contrast agent and interacts with β-amyloid aggregates producing changes in relaxation rate and fluorescence emission.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alzheimer Disease / diagnostic imaging
-
Amyloid / chemistry
-
Amyloid / metabolism*
-
Contrast Media / chemistry*
-
Coordination Complexes / chemistry
-
Fluorescent Dyes / chemistry
-
Gadolinium / chemistry
-
Humans
-
Magnetic Resonance Imaging
-
Radiography
Substances
-
Amyloid
-
Contrast Media
-
Coordination Complexes
-
Fluorescent Dyes
-
Gadolinium